Please login to the form below

Not currently logged in
Email:
Password:

Rubius Therapeutics poaches Novartis’ Spencer Fisk

He joins the US biotech as its senior VP manufacturing

Novartis’ former vice president and global head of cell and gene technical development and manufacturing Spencer Fisk has decided to join Rubius Therapeutics.

He takes up its senior vice president of manufacturing role as the company is looking to expand its manufacturing and development organisations.

Torben Straight Nissen, president of Rubius Therapeutics, said: “Spencer’s expertise and decades of experience in process development and manufacturing will be invaluable and I look forward to working closely together as we continue to deliver on the promise of the next generation of cellular therapies for patients in need.”

Prior to his new role, Fisk spent the last six years at Novartis where he led the CMC development-manufacturing organisation to deliver the CAR-T portfolio of the company.

He has also held a series of leadership positions for both Merck and Schering Plough.

Fish said: “Rubius is developing an entirely new class of ready-to-use cell therapeutics to treat cancer, autoimmune disorders and rare diseases.

“I look forward to leveraging the expertise i've gained while working with larger pharmaceutical companies to help Rubius take its extraordinary RTC pipeline into the clinic.”

6th March 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics